Novo Nordisk A/S: Insider Trading Activity by Board Members, Executives, and Associated Persons

Chart showing recent insider buy and sell transactions for Novo Nordisk A/S board members and executives, with values in DKK.

“Novo Nordisk insiders have shown mixed but notable activity in recent months, with a board member purchasing shares signaling confidence amid broader company challenges, while an executive vice president conducted both buys and sells. Overall net activity leans toward modest selling in value terms, occurring against a backdrop of stock volatility driven by guidance adjustments, … Read more

Eli Lilly’s GLP-1 Dominance: Positioning for Multi-Decade Wealth Creation in the Obesity Revolution

Eli Lilly corporate headquarters building with modern architecture and company logo, representing leadership in GLP-1 obesity drugs.

Eli Lilly has seized leadership in the GLP-1 market with tirzepatide-based Mounjaro and Zepbound, driving explosive revenue growth and capturing over 60% U.S. market share. Recent results show combined tirzepatide sales exceeding $36 billion in 2025, with Q4 alone topping $11 billion amid triple-digit gains. The company guides $80-83 billion in 2026 revenue, fueled by … Read more